Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology

被引：13

作者：

Stump, Craig A. ^{[1
]}

Cooke, Andrew J. ^{[1
]}

Bruno, Joseph ^{[4
]}

Cabalu, Tamara D. ^{[3
]}

Gotter, Anthony L. ^{[2
]}

Harell, C. Meacham ^{[2
]}

Kuduk, Scott D. ^{[1
]}

McDonald, Terrence P. ^{[2
]}

O'Brien, Julie ^{[4
]}

Renger, John J. ^{[2
]}

Williams, Peter D. ^{[1
]}

Winrow, Christopher J. ^{[2
]}

Coleman, Paul J. ^{[1
]}

机构：

[1] Merck Res Labs, Discovery Chem, West Point, PA 19486 USA

[2] Merck Res Labs, Neurosci, West Point, PA 19486 USA

[3] Merck Res Labs, Pharmacokinet Pharmacodynam & Drug Metab, West Point, PA 19486 USA

[4] Merck Res Labs, Vitro Pharmacol, West Point, PA 19486 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2016年 / 26卷 / 23期

关键词：

Selective orexin receptor antagonist (SORA); Dual orexin receptor antagonist (DORA); Orexin-1; Suvorexant; Filorexant; HUMAN NARCOLEPSY; SLEEP; INSOMNIA;

D O I：

10.1016/j.bmcl.2016.10.019

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

While a correlation between blockade of the orexin 2 receptor (OX2R) with either a dual orexin receptor antagonist (DORA) or a selective orexin 2 receptor antagonist (2-SORA) and a decrease of wakefulness is well established, less is known about selective blockade of the orexin 1 receptor (OX1R). Therefore, a highly selective orexin 1 antagonist (1-SORA) with suitable properties to allow in vivo interrogation of OX1R specific pharmacology in preclinical species remains an attractive target. Herein, we describe the discovery of an optimized 1-SORA series in the piperidine ether class. Notably, a 4,4-difluoropiperidine core coupled with a 2-quinoline ether linkage provides OX1R selective compounds. The combination with an azabenzimidazole or imidazopyridine amide substituent leads to analogs 47 and 51 with > 625-fold functional selectivity for OX1R over OX2R in rat. Compounds 47 and 51 possess clean off-target profiles and the required pharmacokinetic and physical properties to be useful as 1-SORA tool compounds. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：5809 / 5814

页数：6

共 23 条

[1]

[Anonymous], 2014, Patent Application WO, Patent No. [2014/113303 A1, 2014113303]

[2] Narcolepsy in orexin knockout mice:: Molecular genetics of sleep regulation [J].

Chemelli, RM ;

Willie, JT ;

Sinton, CM ;

Elmquist, JK ;

Scammell, T ;

Lee, C ;

Richardson, JA ;

Williams, SC ;

Xiong, YM ;

Kisanuki, Y ;

Fitch, TE ;

Nakazato, M ;

Hammer, RE ;

Saper, CB ;

Yanagisawa, M .

CELL, 1999, 98 (04) :437-451

[3] Discovery of [(2R,5R)-5-{[(5-Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): A Dual Orexin Receptor Antagonist with Potent Sleep-Promoting Properties [J].

Coleman, Paul J. ;

Schreier, John D. ;

Cox, Christopher D. ;

Breslin, Michael J. ;

Whitman, David B. ;

Bogusky, Michael J. ;

McGaughey, Georgia B. ;

Bednar, Rodney A. ;

Lemaire, Wei ;

Doran, Scott M. ;

Fox, Steven V. ;

Garson, Susan L. ;

Gotter, Anthony L. ;

Harrell, C. Meacham ;

Reiss, Duane R. ;

Cabalu, Tamara D. ;

Cui, Donghui ;

Prueksaritanont, Thomayant ;

Stevens, Joanne ;

Tannenbaum, Pamela L. ;

Ball, Richard G. ;

Stellabott, Joyce ;

Young, Steven D. ;

Hartman, George D. ;

Winrow, Christopher J. ;

Renger, John J. .

CHEMMEDCHEM, 2012, 7 (03) :415-424

[4] Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia [J].

Cox, Christopher D. ;

Breslin, Michael J. ;

Whitman, David B. ;

Schreier, John D. ;

McGaughey, Georgia B. ;

Bogusky, Michael J. ;

Roecker, Anthony J. ;

Mercer, Swati P. ;

Bednar, Rodney A. ;

Lemaire, Wei ;

Bruno, Joseph G. ;

Reiss, Duane R. ;

Harrell, C. Meacham ;

Murphy, Kathy L. ;

Garson, Susan L. ;

Doran, Scott M. ;

Prueksaritanont, Thomayant ;

Anderson, Wayne B. ;

Tang, Cuyue ;

Roller, Shane ;

Cabalu, Tamara D. ;

Cui, Donahui ;

Hartman, George D. ;

Young, Steven D. ;

Koblan, Ken S. ;

Winrow, Christopher J. ;

Renger, John J. ;

Coleman, Paul J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) :5320-5332

[5] The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity [J].

De Lecea, L ;

Kilduff, TS ;

Peyron, C ;

Gao, XB ;

Foye, PE ;

Danielson, PE ;

Fukuhara, C ;

Battenberg, ELF ;

Gautvik, VT ;

Bartlett, FS ;

Frankel, WN ;

van den Pol, AN ;

Bloom, FE ;

Gautvik, KM ;

Sutcliffe, JG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :322-327

[6] The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold [J].

Gotter, Anthony L. ;

Winrow, Christopher J. ;

Brunner, Joseph ;

Garson, Susan L. ;

Fox, Steven V. ;

Binns, Jacquelyn ;

Harrell, Charles M. ;

Cui, Donghui ;

Yee, Ka Lai ;

Stiteler, Mark ;

Stevens, Joanne ;

Savitz, Alan ;

Tannenbaum, Pamela L. ;

Tye, Spencer J. ;

McDonald, Terrence ;

Yao, Leon ;

Kuduk, Scott D. ;

Uslaner, Jason ;

Coleman, Paul J. ;

Renger, John J. .

BMC NEUROSCIENCE, 2013, 14

[7] International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology [J].

Gotter, Anthony L. ;

Webber, Andrea L. ;

Coleman, Paul J. ;

Renger, John J. ;

Winrow, Christopher J. .

PHARMACOLOGICAL REVIEWS, 2012, 64 (03) :389-420

[8] Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate [J].

Letavic, Michael A. ;

Bonaventure, Pascal ;

Carruthers, Nicholas I. ;

Dugovic, Christine ;

Koudriakova, Tatiana ;

Lord, Brian ;

Lovenberg, Timothy W. ;

Ly, Kiev S. ;

Mani, Neelakandha S. ;

Nepomuceno, Diane ;

Pippel, Daniel J. ;

Rizzolio, Michele ;

Shelton, Jonathan E. ;

Shah, Chandra R. ;

Shireman, Brock T. ;

Young, Lana K. ;

Yun, Sujin .

JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (14) :5620-5636

[9] The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene [J].

Lin, L ;

Faraco, J ;

Li, R ;

Kadotani, H ;

Rogers, W ;

Lin, XY ;

Qiu, XH ;

de Jong, PJ ;

Nishino, S ;

Mignot, E .

CELL, 1999, 98 (03) :365-376

[10] The Dual Orexin Receptor Antagonist Almorexant Induces Sleep and Decreases Orexin-Induced Locomotion by Blocking Orexin 2 Receptors [J].

Mang, Geraldine M. ;

Duerst, Thomas ;

Buerki, Hugo ;

Imobersteg, Stefan ;

Abramowski, Dorothee ;

Schuepbach, Edi ;

Hoyer, Daniel ;

Fendt, Markus ;

Gee, Christine E. .

SLEEP, 2012, 35 (12) :1625-1635

← 1 2 3 →